| 000 | 01485 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250514170058.0 | ||
| 264 | 0 | _c20040513 | |
| 008 | 200405s 0 0 eng d | ||
| 022 | _a0362-1642 | ||
| 024 | 7 |
_a10.1146/annurev.pharmtox.44.101802.121840 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Leo H | |
| 245 | 0 | 0 |
_aMixed-lineage kinases: a target for the prevention of neurodegeneration. _h[electronic resource] |
| 260 |
_bAnnual review of pharmacology and toxicology _c2004 |
||
| 300 |
_a451-74 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAlzheimer Disease _xenzymology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCarbazoles _xpharmacology |
| 650 | 0 | 4 |
_aHearing Loss _xphysiopathology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIndole Alkaloids |
| 650 | 0 | 4 |
_aIndoles _xpharmacology |
| 650 | 0 | 4 | _aJNK Mitogen-Activated Protein Kinases |
| 650 | 0 | 4 |
_aMAP Kinase Kinase Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aMitogen-Activated Protein Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aNeurodegenerative Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xpharmacology |
| 650 | 0 | 4 |
_aParkinson Disease _xenzymology |
| 700 | 1 | _aBesirli, Cagri G | |
| 700 | 1 | _aJohnson, Eugene M | |
| 773 | 0 |
_tAnnual review of pharmacology and toxicology _gvol. 44 _gp. 451-74 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1146/annurev.pharmtox.44.101802.121840 _zAvailable from publisher's website |
| 999 |
_c14469030 _d14469030 |
||